Skip to main content
. 2014 Feb;348(2):293–302. doi: 10.1124/jpet.113.205120

Fig. 1.

Fig. 1.

WIN2 stereoselectively and dose dependently inhibits the growth of breast cancer cells. Growth inhibition by WIN2 and WIN3 was assessed at 96 hours post-treatment by the crystal violet assay in MCF-7 (A), MDA-MB231 (B), and 4T1 breast tumor cells (C). Data presented reflect the means of 4 individual experiments ± S.E.; *P < 0.05 versus WIN3 at each respective concentration of drug.